Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Gastric Cancer

Free Subscription Articles published in Anticancer Res Retrieve available abstracts of 98 articles: HTML format

Single Articles

July 2025
1. SASAKI K, Fujita K, Fujihara S, Iwama H, et al
   The Polyphenol (-)-Epigallocatechin-3-gallate (EGCG) Inhibits the Proliferation of Gastric Cancer Cells and Alters microRNA Signatures.
   Anticancer Res. 2025;45:2925-2936.
   PubMed     Abstract available
   
   
   June 2025
2. BASKAR S, Schoeneich R, Grewal US
   In-hospital Outcomes Between Total Parenteral Nutrition and Enteral Feeding in Esophageal and Gastric Cancer: A Nationwide Analysis.
   Anticancer Res. 2025;45:2453-2457.
   PubMed     Abstract available
   
   
   May 2025
3. KANG M, Kim KJ, Sung JH, Nam M, et al
   Development of Acquired Resistance in Alpelisib-treated Gastric Cancer Cells With PIK3CA Mutations and Overcoming Strategies.
   Anticancer Res. 2025;45:1877-1896.
   PubMed     Abstract available
   
   
   
4. HOJO Y, Tomita T, Igeta M, Murakami M, et al
   Impact of Nivolumab Plus Chemotherapy on Conversion Therapy in Clinical Stage IVB HER2-negative Gastric Cancer.
   Anticancer Res. 2025;45:2091-2102.
   PubMed     Abstract available
   
   
   
5. ZHOU N, Yuan Y, Lin H, Wang J, et al
   Epigallocatechin Gallate Induces miR-192/215 Suppression of EGR1 in Gastric Cancer.
   Anticancer Res. 2025;45:1935-1951.
   PubMed     Abstract available
   
   
   
6. LAI LW, Yamashita T, Otsuka K, Saito A, et al
   Rare Upper Mediastinal Oligometastasis from Early Esophagogastric Adenocarcinoma: A Case Report.
   Anticancer Res. 2025;45:2109-2114.
   PubMed     Abstract available
   
   
   
7. JANG BI, Jung JY, Koh SA, Park YE, et al
   MAP17 as a Mediator of HGF-induced Proliferation and Invasion in Gastric Cancer.
   Anticancer Res. 2025;45:2011-2024.
   PubMed     Abstract available
   
   
   April 2025
8. LIM SC, Lee TB, Han SI
   Caffeic Acid Phenethyl Ester Inhibits Metastatic Properties of Acid-adapted Gastric Cancer Cells.
   Anticancer Res. 2025;45:1525-1534.
   PubMed     Abstract available
   
   
   
9. FURUSAWA K, Furuta M, Onishi M, Hama T, et al
   Nivolumab Plus 5-Fluorouracil/Leucovorin+Oxaliplatin for Gastric Cancer With Severe Peritoneal Metastasis.
   Anticancer Res. 2025;45:1583-1592.
   PubMed     Abstract available
   
   
   
10. TAKAHASHI T, Matsunaga T, Saito H, Osaki T, et al
    Comparison of Postoperative Outcomes of Laparoscopic Versus Open Gastrectomy in Older Patients With Gastric Cancer.
    Anticancer Res. 2025;45:1667-1679.
    PubMed     Abstract available
    
    
    
11. FUTAWATARI N, Fukuyama T, Akimoto Y, Maehara J, et al
    Association Between Kita-kyushu Lung Cancer Antigen-1 Expression in Gastric Cancer and Helicobacter pylori-infection Status.
    Anticancer Res. 2025;45:1599-1606.
    PubMed     Abstract available
    
    
    
12. IZUTSU R, Osaki M, Seong H, Sato R, et al
    Hepatic Stellate Cells Activated by Cancer Cell-derived AMIGO2-containing Small Extracellular Vesicles Promote Cancer Cell Migration by Producing IL-8.
    Anticancer Res. 2025;45:1435-1446.
    PubMed     Abstract available
    
    
    
13. KURODA K, Toyokawa T, Tsujio G, Miki Y, et al
    Significance of Systemic Inflammatory Markers as Prognostic Predictors in Stage II/III Gastric Cancer Among Older Patients.
    Anticancer Res. 2025;45:1681-1694.
    PubMed     Abstract available
    
    
    March 2025
14. IMAI T, Futamura M, Mori R, Yasufuku I, et al
    Expression of the Niemann-Pick C1-like 1 Protein in Gastric Cancer.
    Anticancer Res. 2025;45:965-975.
    PubMed     Abstract available
    
    
    
15. ESASHI R, Aoyama T, Yamamoto S, Maezawa Y, et al
    The CONUT Score Can Predict the Prognosis of Gastric Cancer Patients After Curative Treatment.
    Anticancer Res. 2025;45:1251-1260.
    PubMed     Abstract available
    
    
    
16. KAWADA J, Sakai D, Kimura Y, Hirao M, et al
    A Phase II Trial of Trastuzumab Combined With Irinotecan in Patients With Advanced HER2-positive Chemotherapy-refractory Gastric Cancer (OGSG1203 HERBIS-5): Final Results.
    Anticancer Res. 2025;45:1077-1085.
    PubMed     Abstract available
    
    
    
17. KOMORI K, Yamada T, Ando S, Nagasawa S, et al
    Clinical Significance of Residual Lymph Node Metastasis in Predicting Recurrence After Preoperative Chemotherapy and Surgery for Gastric Cancer.
    Anticancer Res. 2025;45:1205-1214.
    PubMed     Abstract available
    
    
    February 2025
18. HUANG CJ, Shieh PC, Yang JS, Li YC, et al
    Pterostilbene Suppressed Cell Viability, Induced Apoptosis and Autophagy of Cisplatin-resistant Gastric Cancer Cells.
    Anticancer Res. 2025;45:511-523.
    PubMed     Abstract available
    
    
    
19. KOMORI K, Abiko F, Ichikawa T, Ando K, et al
    Impact of Perioperative Rehabilitation on Postoperative Length of Hospital Stay for Patients With Gastric Cancer.
    Anticancer Res. 2025;45:817-822.
    PubMed     Abstract available
    
    
    January 2025
20. SUGIMOTO N, Kawada J, Oka Y, Ueda S, et al
    Salvage-line of Capecitabine Plus Oxaliplatin Therapy (XELOX) for Patients With Inoperable/Advanced Gastric Cancer Resistant/Intolerant to Cisplatin (OGSG1403).
    Anticancer Res. 2025;45:307-313.
    PubMed     Abstract available
    
    
    
21. TSURUDA Y, Masuda T, Hiraki Y, Kitagawa M, et al
    Circulating Pre-microRNA-488 in Blood Is a Potential Prognostic Biomarker in Gastric Cancer.
    Anticancer Res. 2025;45:123-133.
    PubMed     Abstract available
    
    
    December 2024
22. ZHOU F, Zhuo J, Xu X, Pan D, et al
    Circular RNA hsa_circ_0004650 Enhances 5-Fluorouracil Resistance in Gastric Cancer via Sponging miR-145-5p.
    Anticancer Res. 2024;45:173-187.
    PubMed     Abstract available
    
    
    
23. AOYAMA T, Hashimoto I, Maezawa Y, Esashi R, et al
    Perioperative Anemia Is an Independent Prognostic Factor for Gastric Cancer Patients Who Receive Curative Treatment.
    Anticancer Res. 2024;44:5551-5557.
    PubMed     Abstract available
    
    
    November 2024
24. FUJIMOTO D, Kobayashi H
    PAR1 Is a Candidate Target for the Treatment of Peritoneal Dissemination in Gastric Cancer.
    Anticancer Res. 2024;44:4857-4867.
    PubMed     Abstract available
    
    
    
25. OSHIMA T, Yoshikawa T, Miyagi Y, Morita S, et al
    Biomarker Study for Selecting Neoadjuvant Chemotherapy Regimens Based on Prognostic Prediction Using Gastric Cancer Biopsy Specimens from a Phase II Randomized Controlled Trial.
    Anticancer Res. 2024;44:4951-4960.
    PubMed     Abstract available
    
    
    
26. FU CK, Lee HT, Chen JC, Yang MD, et al
    Contributions of Tissue Inhibitor of Metalloproteinase-1 Genotypes to the Risk of Metastasis in Gastric Cancer.
    Anticancer Res. 2024;44:4833-4841.
    PubMed     Abstract available
    
    
    
27. HIGASHI T, Kimura M, Kato Y, Hattori K, et al
    Impact of Pre-operative Lymphocyte and Albumin Combination on Adjuvant Chemotherapy and Prognosis of Gastric Cancer.
    Anticancer Res. 2024;44:5051-5058.
    PubMed     Abstract available
    
    
    
28. FUJIYA K, Serizawa M, Ohshima K, Umehara R, et al
    A Gene Expression Signature that Predicts Gastric Cancer Sensitivity to PARP Inhibitor Therapy.
    Anticancer Res. 2024;44:4779-4788.
    PubMed     Abstract available
    
    
    October 2024
29. FU CK, Chien WC, Chen YJ, Yang MD, et al
    Impacts of Matrix Metalloproteinase-8 Genotypes, Smoking, Alcohol Drinking, and Helicobacter Pylori Infection on Gastric Cancer.
    Anticancer Res. 2024;44:4225-4232.
    PubMed     Abstract available
    
    
    
30. OSHIMA T, Hashimoto I, Hiroshima Y, Kimura Y, et al
    Clinical Significance of Granzyme B Gene Expression in Pathological Stage II/III Gastric Cancer After Curative Gastrectomy.
    Anticancer Res. 2024;44:4537-4542.
    PubMed     Abstract available
    
    
    
31. BYEON SJ, Chang MS, Park HE, Kang D, et al
    Predictive Biomarkers of Lymph Node Metastasis in Early Gastric Cancer: A Reference of Clinicopathological Characteristics, Protein Expression, Epstein-Barr Virus Status, and Microsatellite Instability.
    Anticancer Res. 2024;44:4435-4448.
    PubMed     Abstract available
    
    
    
32. OSHIMA T, Hashimoto I, Hiroshima Y, Kimura Y, et al
    Clinical Significance of HRNR Expression in Patients With Stage II/III Gastric Cancer After Curative Gastrectomy.
    Anticancer Res. 2024;44:4579-4584.
    PubMed     Abstract available
    
    
    September 2024
33. AOYAMA T, Maezawa Y, Hashimoto I
    Open, Laparoscopy-assisted, Robotic-assisted Distal Gastrectomy for Gastric Cancer: Evidence from Randomized Clinical Trials.
    Anticancer Res. 2024;44:3737-3745.
    PubMed     Abstract available
    
    
    
34. ARIGAMI T, Matsushita D, Shimonosono M, Hirase Y, et al
    Clinical Significance of Body Weight Loss During Chemotherapy for Advanced Gastric Cancer Undergoing Conversion Surgery.
    Anticancer Res. 2024;44:4031-4037.
    PubMed     Abstract available
    
    
    
35. HASHIMOTO I, Nakayama Y, Tanabe M, Morita J, et al
    Inflammatory Burden Index Prognostic Impact in Patients With Gastric Cancer After Gastrectomy: A Propensity Score-matched Analysis.
    Anticancer Res. 2024;44:3995-4001.
    PubMed     Abstract available
    
    
    August 2024
36. HASHIMOTO I, Komori K, Onuma S, Watanabe H, et al
    Preoperative Visceral-to-Subcutaneous Fat Ratio by Sex as a Predictor of Postoperative Survival in Patients With Gastric Cancer.
    Anticancer Res. 2024;44:3515-3524.
    PubMed     Abstract available
    
    
    July 2024
37. SATO Y, Yamashita H, Yagi K, Nomura S, et al
    Ramucirumab Beyond Disease Progression After Paclitaxel Plus Ramucirumab in Gastric Cancer: A Phase II Trial.
    Anticancer Res. 2024;44:3125-3131.
    PubMed     Abstract available
    
    
    June 2024
38. TAKAHASHI N, Fujisaki M, Takano Y, Takeshita K, et al
    New Proposal Strategy of Sentinel Lymph Node Navigation Surgery for Endoscopic Curability C-2: A Retrospective Study.
    Anticancer Res. 2024;44:2717-2724.
    PubMed     Abstract available
    
    
    
39. LI Y, Tazawa H, Nagai Y, Fujita S, et al
    Senescent Fibroblasts Potentiate Peritoneal Metastasis of Diffuse-type Gastric Cancer Cells via IL-8-mediated Crosstalk.
    Anticancer Res. 2024;44:2497-2509.
    PubMed     Abstract available
    
    
    
40. PARK JW, Kim W, Kang HG, Kim WJ, et al
    DNA Hypermethylation Inhibits the CD82 Metastasis Suppressor Gene in Gastric Cancer.
    Anticancer Res. 2024;44:2459-2470.
    PubMed     Abstract available
    
    
    
41. KOMORI K, Yamada T, Ando S, Hashimoto I, et al
    Comparison of Survival Between ypStage and pStage in Gastric Cancer.
    Anticancer Res. 2024;44:2661-2670.
    PubMed     Abstract available
    
    
    May 2024
42. SUN SL, Sarofim M, Morris DL
    Transhepatic Bromelain and Acetylcysteine for Treatment of Posterior Gastric Pseudomyxoma Peritonei: A Case Report.
    Anticancer Res. 2024;44:2239-2241.
    PubMed     Abstract available
    
    
    
43. SHIROSAKI T, Kawai N, Ebihara Y, Murai A, et al
    Aldehyde Dehydrogenese-1 High Cancer Stem-like Cells/Cancer-initiating Cells Escape from Cytotoxic T Lymphocytes due to Lower Expression of Human Leukocyte Antigen Class 1.
    Anticancer Res. 2024;44:1877-1883.
    PubMed     Abstract available
    
    
    
44. AOYAMA T, Hashimoto I, Maezawa Y, Hara K, et al
    The Clinical Impact of the Prognostic Immune and Nutritional Index in Gastric Cancer Patients Who Received Curative Treatment.
    Anticancer Res. 2024;44:2231-2238.
    PubMed     Abstract available
    
    
    
45. JUNG JY, Koh SA, Lee KH
    Cold-shock Domain Protein A (CSDA) Influences Hepatocyte Growth Factor-medicated Cell Proliferation and Metastasis in Gastric Cancer Cells.
    Anticancer Res. 2024;44:1973-1981.
    PubMed     Abstract available
    
    
    
46. KUM SJ, Jung YY, Kim HS
    Comparison of Clinicopathological and Prognostic Characteristics Between Minimal Deviation Adenocarcinoma and Gastric-type Endocervical Adenocarcinoma.
    Anticancer Res. 2024;44:2193-2204.
    PubMed     Abstract available
    
    
    April 2024
47. AOYAMA T, Hashimoto I, Maezawa Y, Hara K, et al
    Clinical Impact of the Lymphocyte-to-Monocyte Ratio in Patients With Gastric Cancer who Received Curative Treatment.
    Anticancer Res. 2024;44:1567-1574.
    PubMed     Abstract available
    
    
    
48. HWANG SH, Kim DJ
    Nomogram for Predicting Infectious Complications Following Curative Gastrectomy Using Clinical and Laboratory Parameters.
    Anticancer Res. 2024;44:1781-1790.
    PubMed     Abstract available
    
    
    
49. NUMAKURA S, Uozaki H
    Gastric Cancer With the Increased Nicotinamide N-methyltransferase-positive Stromal Cells Includes Unfavorable Prognosis-related Cancer-associated Fibroblasts.
    Anticancer Res. 2024;44:1653-1660.
    PubMed     Abstract available
    
    
    
50. MORINO K, Yamamoto M, Shimoike N, Iwasaki Y, et al
    Safety and Limitations of Laparoscopic Total Gastrectomy for Gastric Cancer: A Comparative Analysis of Short and Long-term Outcomes With Open Surgery.
    Anticancer Res. 2024;44:1759-1766.
    PubMed     Abstract available
    
    
    
51. AOYAMA T, Maezawa Y, Hashimoto I, Hara K, et al
    The CRP-albumin-lymphocyte (CALLY) Index Is an Independent Prognostic Factor for Gastric Cancer Patients who Receive Curative Treatment.
    Anticancer Res. 2024;44:1629-1636.
    PubMed     Abstract available
    
    
    
52. AGATSUMA Y, Nakanishi K, Tanaka C, Kanda M, et al
    Risk Factors for Long-term Body Weight Loss After Proximal Gastrectomy: A Retrospective Analysis.
    Anticancer Res. 2024;44:1645-1651.
    PubMed     Abstract available
    
    
    
53. CHEN G, Shang J, Feng X, Li M, et al
    Hsa_circTCF25 Facilitates Oncogenesis in Gastric Cancer Cells by Modulating miR-149 Expression.
    Anticancer Res. 2024;44:1475-1485.
    PubMed     Abstract available
    
    
    February 2024
54. OSHIMA T, Hashimoto I, Hiroshima Y, Kimura Y, et al
    Clinical Significance of Tryptophanyl-tRNA Synthetase 1 Gene Expression in Patients With Locally Advanced Gastric Cancer.
    Anticancer Res. 2024;44:673-678.
    PubMed     Abstract available
    
    
    
55. KONDO J, Yoshino S, Iida M, Takeda S, et al
    Effects of Extended Fixation on Advanced Gastric Cancer HER2 Status Assessment Using IHC and FISH.
    Anticancer Res. 2024;44:621-630.
    PubMed     Abstract available
    
    
    
56. TANABE M, Aoyama T, Nakazono M, Morita J, et al
    Comparison of Dietary Intake After Gastric Cancer Gastrectomy Between Patients With and Without Postoperative Surgical Complications.
    Anticancer Res. 2024;44:839-844.
    PubMed     Abstract available
    
    
    
57. MATSUMOTO T, Toya R, Shimohigashi Y, Yamaguchi K, et al
    Influence of Respiratory Motion on Dose Distribution in Gastric Mucosa-associated Lymphoid Tissue Lymphoma Radiotherapy.
    Anticancer Res. 2024;44:687-694.
    PubMed     Abstract available
    
    
    
58. TAKAHASHI N, Takano Y, Takeshita K, Toya N, et al
    Proctoring System Enables Safe Induction of Robotic Gastrectomy: Short-term Outcomes of the First 10 Cases.
    Anticancer Res. 2024;44:823-828.
    PubMed     Abstract available
    
    
    January 2024
59. ITO S, Kuramochi H, Serizawa A, Ota M, et al
    Long-term Results of a Phase II Study of Neoadjuvant SOX for Advanced Gastric Cancer.
    Anticancer Res. 2024;44:195-204.
    PubMed     Abstract available
    
    
    
60. OSHIMA T, Hashimoto I, Hiroshima Y, Kimura Y, et al
    Asialoglycoprotein Receptor 2 Expression in Patients With Locally Advanced Gastric Cancer After Curative Resection.
    Anticancer Res. 2024;44:397-402.
    PubMed     Abstract available
    
    
    
61. SHIMONOSONO M, Arigami T, Matsushita D, Tsuruda Y, et al
    Evaluation of Quality of Life and Prognosis of Gastric Cancer Patients After Laparoscopic Subtotal Gastrectomy.
    Anticancer Res. 2024;44:387-396.
    PubMed     Abstract available
    
    
    
62. OSHIMA T, Hashimoto I, Hiroshima Y, Kimura Y, et al
    Clinical Significance of Pregnancy Zone Protein Expression in Patients With Locally Advanced Gastric Cancer After Curative Resection.
    Anticancer Res. 2024;44:369-374.
    PubMed     Abstract available
    
    
    
63. OSHIMA T, Hashimoto I, Hiroshima Y, Kimura Y, et al
    Clinical Significance of Chitinase-3-like Protein 1 Gene Expression in Patients With Locally Advanced Gastric Cancer.
    Anticancer Res. 2024;44:307-312.
    PubMed     Abstract available
    
    
    
64. MORITA J, Aoyama T, Nakazono M, Tanabe M, et al
    Dietary Intake After Surgery in Patients With Gastric Cancer Who Underwent Laparoscopic-assisted Versus Those Who Underwent Conventional Gastrectomy.
    Anticancer Res. 2024;44:409-415.
    PubMed     Abstract available
    
    
    December 2023
65. AOYAMA T, Maezawa Y, Hashimoto I, Hara K, et al
    The Clinical Influence of Geriatric Nutritional Risk Index in Patients With Gastric Cancer Who Receive Curative Treatment.
    Anticancer Res. 2023;43:5605-5612.
    PubMed     Abstract available
    
    
    
66. SATO S, Kunisaki C, Tamura Y, Yago A, et al
    Ramucirumab Plus Paclitaxel as a Second-line Chemotherapy in Older Adults With Advanced Gastric Cancer (YCOG1601).
    Anticancer Res. 2023;43:5663-5670.
    PubMed     Abstract available
    
    
    
67. MUKOYAMA T, Kanaji S, Sawada R, Harada H, et al
    Safety and Efficacy of Neoadjuvant Chemotherapy for Advanced Gastric Cancer in Elderly Patients.
    Anticancer Res. 2023;43:5649-5656.
    PubMed     Abstract available
    
    
    November 2023
68. OTSUKA R, Hayashi H, Uesato M, Hayano K, et al
    Inflammatory and Nutritional Indices as Prognostic Markers in Elderly Patients With Gastric Cancer.
    Anticancer Res. 2023;43:5261-5267.
    PubMed     Abstract available
    
    
    
69. AOYAMA T, Hashimoto I, Maezawa Y, Hara K, et al
    The C-reactive Protein to Prealbumin Ratio Is an Independent Prognostic Factor for Patients With Gastric Cancer Who Receive Curative Surgery.
    Anticancer Res. 2023;43:5181-5187.
    PubMed     Abstract available
    
    
    
70. HORI N, Tazawa H, Li Y, Okura T, et al
    Intraperitoneal Administration of p53-armed Oncolytic Adenovirus Inhibits Peritoneal Metastasis of Diffuse-type Gastric Cancer Cells.
    Anticancer Res. 2023;43:4809-4821.
    PubMed     Abstract available
    
    
    
71. SANO A, Sohda M, Hosoi N, Tateno K, et al
    Importance of Progression-free Survival in Second-line Chemotherapy in Patients With Advanced or Recurrent Gastric Cancer.
    Anticancer Res. 2023;43:5205-5213.
    PubMed     Abstract available
    
    
    
72. YAMAMOTO M, Omori T, Shinno N, Hara H, et al
    Adjuvant Chemotherapy With S-1 Plus Docetaxel Versus S-1 Plus Oxaliplatin in Stage III Gastric Cancer.
    Anticancer Res. 2023;43:5015-5024.
    PubMed     Abstract available
    
    
    
73. MATSUNAGA T, Satio H, Sakano YU, Makinoya M, et al
    Skeletal Muscle Mass Before Second-line Chemotherapy Correlates With Subsequent Prognosis and Rate of Late-line Chemotherapy in Patients With Unresectable Gastric Cancer.
    Anticancer Res. 2023;43:5051-5059.
    PubMed     Abstract available
    
    
    
74. KITAGAWA H, Hiraki M, Namba T, Baba K, et al
    The Oncological Effect of Mutant p53 on the Metastatic Phenotype of Gastric Cancer Cells.
    Anticancer Res. 2023;43:4887-4895.
    PubMed     Abstract available
    
    
    October 2023
75. TSUJIO G, Yashiro M, Sakuma T, Aoyama R, et al
    Impact of SMAD2 and MET Expression on Lymph Node Metastasis of HER2-positive Gastric Cancer Cells.
    Anticancer Res. 2023;43:4359-4364.
    PubMed     Abstract available
    
    
    
76. ZHANG YQ, Shi SS, Li YF, Yang Y, et al
    Melatonin Inhibits Gastric Cancer Cell Proliferation by Suppressing Exosome miR-27b-3p Expression.
    Anticancer Res. 2023;43:4413-4424.
    PubMed     Abstract available
    
    
    
77. DU L, Xie F, Han H, Zhang L, et al
    Targeting SALL4 by Entinostat Inhibits the Malignant Phenotype of Gastric Cancer Cells by Reducing EMT Signaling.
    Anticancer Res. 2023;43:4389-4401.
    PubMed     Abstract available
    
    
    September 2023
78. IWASAKI H, Haraguchi E, Ihashi T, Yokomizo H, et al
    Risk Factor of Sarcopenia After Gastrectomy in Elderly Patients With Gastric Cancer.
    Anticancer Res. 2023;43:4207-4212.
    PubMed     Abstract available
    
    
    August 2023
79. SHIMIZU S, Matsunaga T, Sawata S, Sakano YU, et al
    Preoperative Osteopenia Is a Risk Factor for Death in Patients Undergoing Gastrectomy for Gastric Cancer.
    Anticancer Res. 2023;43:3665-3672.
    PubMed     Abstract available
    
    
    
80. ENDO S, Yamada T, Kawada J, Higashida M, et al
    Proximal Resection Line Determination Using Intraoperative Radiography in Laparoscopic Distal Gastrectomy for Gastric Cancer.
    Anticancer Res. 2023;43:3685-3691.
    PubMed     Abstract available
    
    
    
81. TANAKA Y, Aoyagi K, Umetani Y, Tanaka YU, et al
    Impact of Skeletal Muscle Mass Reduction on Long-term Survival After Radical Resection of Gastric Cancer.
    Anticancer Res. 2023;43:3779-3786.
    PubMed     Abstract available
    
    
    July 2023
82. ARIGAMI T, Matsushita D, Shimonosono M, Tsuruda Y, et al
    Clinical Significance of Recurrence Risk Score for Conversion Surgery in Patients With Advanced Gastric Cancer.
    Anticancer Res. 2023;43:3305-3310.
    PubMed     Abstract available
    
    
    
83. KANAJI S, Urakawa N, Mukoyama T, Harada H, et al
    Safety of Laparoscopic Gastrectomy for Advanced Gastric Cancer With Greater than Serosal Invasion Depth.
    Anticancer Res. 2023;43:3145-3152.
    PubMed     Abstract available
    
    
    
84. DAVAKIS S, Kapelouzou A, Sakellariou S, Kyriakoulis KG, et al
    Clinical and Oncological Impact of the Toll-like Receptor-3 and -4 in Esophageal and Gastro-esophageal Junction Adenocarcinoma.
    Anticancer Res. 2023;43:3183-3191.
    PubMed     Abstract available
    
    
    
85. WOLL E, Amann A, Eisterer W, Gerger A, et al
    Treatment Algorithm for Patients With Gastric Adenocarcinoma: Austrian Consensus on Systemic Therapy - An Update.
    Anticancer Res. 2023;43:2889-2897.
    PubMed     Abstract available
    
    
    June 2023
86. KOMORI K, Kano K, Ando S, Watanabe H, et al
    Clinicopathological Characteristics and Prognosis of Mucinous Gastric Cancer.
    Anticancer Res. 2023;43:2865-2871.
    PubMed     Abstract available
    
    
    
87. SIHOMBING AM, Murata S, Shimoji M, Miyake T, et al
    CD44-positive Cancer Stem-like Cells as a Potential Source of Peritoneal Metastasis After Surgery.
    Anticancer Res. 2023;43:2491-2500.
    PubMed     Abstract available
    
    
    
88. KASAHARA K, Kunisaki C, Sato S, Kondo H, et al
    Long-term Outcomes of Neoadjuvant Chemotherapy With Docetaxel, Cisplatin and S-1 for Stage III Gastric Cancer.
    Anticancer Res. 2023;43:2841-2850.
    PubMed     Abstract available
    
    
    
89. ITO E, Ogino I, Sugiura M, Watanabe S, et al
    Long-term Outcomes of Early-stage Non-stomach Gastrointestinal Mucosa-associated Lymphoid Tissue Lymphoma Treated With Radiation Therapy.
    Anticancer Res. 2023;43:2851-2857.
    PubMed     Abstract available
    
    
    
90. HAYASHI K, Furuta M, Furusawa K, Hamaguchi T, et al
    Evaluation of Irinotecan and Trifluridine/Tipiracil as Fourth-line Treatments After Third-line Nivolumab for Advanced Gastric Cancer.
    Anticancer Res. 2023;43:2831-2840.
    PubMed     Abstract available
    
    
    May 2023
91. MIYAMOTO H, Yoshii M, Tanaka H, Nishi S, et al
    Dorsal Subcutaneous Fat Thickness as a Risk Factor for Pancreatic Fistula After Gastric Cancer Surgery.
    Anticancer Res. 2023;43:2171-2178.
    PubMed     Abstract available
    
    
    
92. ITO S, Ohgaki K, Kawazoe T, Sato S, et al
    Survival Benefits of Laparoscopic Gastrectomy in Elderly Patients With Gastric Cancer: Focusing on Preoperative Nutritional and Inflammatory Status.
    Anticancer Res. 2023;43:2055-2067.
    PubMed     Abstract available
    
    
    
93. YUKAWA N, Yamada T, Aoyama T, Woo T, et al
    Tumor DNA in Peritoneal Lavage as a Novel Biomarker for Predicting Peritoneal Recurrence in Patients With Gastric Cancer.
    Anticancer Res. 2023;43:2069-2076.
    PubMed     Abstract available
    
    
    
94. MORINO K, Yamamoto M, Yamanaka R, Iwasaki Y, et al
    Clinical Impact of Laparoscopic Surgery on the Long-term Survival of Advanced Gastric Cancer Patients With Regard to Facilitating Doublet Adjuvant Chemotherapy.
    Anticancer Res. 2023;43:2203-2209.
    PubMed     Abstract available
    
    
    April 2023
95. YANG YM, Ruge F, Ji KE, Jia S, et al
    ALCAM, Activated Leukocyte Cell Adhesion Molecule, in Clinical Gastric Cancer and Patient's Response to Chemotherapies.
    Anticancer Res. 2023;43:1463-1475.
    PubMed     Abstract available
    
    
    
96. OTSUKA R, Morishita H, Iida K, Hayano K, et al
    Serum Versus Tissue SIRT1 as Potentially Valuable Biomarkers in Gastric Cancer.
    Anticancer Res. 2023;43:1485-1491.
    PubMed     Abstract available
    
    
    
97. HASHIMOTO I, Kano K, Onuma S, Suematsu H, et al
    Clinical Significance of Neutrophil-to-Lymphocyte Ratio/Serum Albumin Ratio in Patients With Metastatic Gastric or Gastroesophageal Junction Cancer Administered Trifluridine/Tipiracil.
    Anticancer Res. 2023;43:1689-1697.
    PubMed     Abstract available
    
    
    
98. AYUB A, Naeem B, Perez A, Tyler D, et al
    Gastric Linitis Plastica: Clinical Characteristics and Outcomes from the National Cancer Database.
    Anticancer Res. 2023;43:1543-1548.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gastric Cancer is free of charge.